These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1342043)

  • 1. Does melatonin mediate the therapeutic effects of 5-HT reuptake inhibitors in obsessive compulsive disorder?
    Sandyk R
    Int J Neurosci; 1992; 64(1-4):221-3. PubMed ID: 1342043
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathogenesis and treatment of obsessive-compulsive disorder.
    Dolberg OT; Iancu I; Sasson Y; Zohar J
    Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using graph theory to connect the dots in obsessive-compulsive disorder.
    Taylor SF
    Biol Psychiatry; 2014 Apr; 75(8):593-4. PubMed ID: 24673774
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of clomipramine in obsessive-compulsive disorder.
    Howland RH
    Anxiety; 1996; 2(1):56-7. PubMed ID: 9160602
    [No Abstract]   [Full Text] [Related]  

  • 8. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
    Humble M; Bejerot S; Bergqvist PB; Bengtsson F
    Biol Psychiatry; 2001 Feb; 49(4):360-8. PubMed ID: 11239907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment.
    Monteleone P; Catapano F; Tortorella A; Di Martino S; Maj M
    Psychoneuroendocrinology; 1995; 20(7):763-70. PubMed ID: 8848522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Drug Ther Bull; 1995 Jun; 33(6):47-8. PubMed ID: 7587998
    [No Abstract]   [Full Text] [Related]  

  • 12. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients.
    Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T
    Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venlafaxine for treatment of obsessive-compulsive disorder.
    Ananth J; Burgoyne K; Smith M; Swartz R
    Am J Psychiatry; 1995 Dec; 152(12):1832. PubMed ID: 8526258
    [No Abstract]   [Full Text] [Related]  

  • 14. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and potential pharmacological treatments for obsessive-compulsive disorder.
    Davidson J; Bjorgvinsson T
    Expert Opin Investig Drugs; 2003 Jun; 12(6):993-1001. PubMed ID: 12783603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
    Farnam A; Goreishizadeh MA; Farhang S
    Arch Iran Med; 2008 Sep; 11(5):522-5. PubMed ID: 18759519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of obsessive-compulsive disorder with venlafaxine.
    Grossman R; Hollander E
    Am J Psychiatry; 1996 Apr; 153(4):576-7. PubMed ID: 8599411
    [No Abstract]   [Full Text] [Related]  

  • 18. Venlafaxine in obsessive-compulsive disorder.
    Yaryura-Tobias JA; Neziroglu FA
    Arch Gen Psychiatry; 1996 Jul; 53(7):653-4. PubMed ID: 8660133
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.
    Kochan LD; Qureshi AI; Fallon BA
    Curr Psychiatry Rep; 2000 Aug; 2(4):327-34. PubMed ID: 11122977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up of obsessive-compulsive patients treated with proserotonergic agents.
    Mundo E; Erzegovesi S; Bellodi L
    J Clin Psychopharmacol; 1995 Aug; 15(4):288-9. PubMed ID: 7593716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.